07.03.2014 • News

Zachert to Take up Post as Lanxess CEO on April 1

Matthias Zachert, CEO-designate of Lanxess, will take up his duties on Apr. 1, the company said.

When it announced the resignation of then-chief executive Axel Heitmann on Jan. 26, Lanxess said its former chief financial officer Zachert - who has held the same position at German chemicals and pharmaceuticals producer Merck KGaA since 2011 - would rejoin the company on May 15 "at the latest."

Until a new CFO for Merck has been found, CEO, Karl-Ludwig Kley will also fill that function.

Lanxess' current CFO, Bernhard Düttmann, who succeeded Heitmann as acting CEO on Feb. 28, will continue in that position until Zachert's return. Düttmann is due to present the company's 2013 balance sheet on Mar. 20; however, a press conference to discuss the results - and present figures for the first quarter of 2014 - has been rescheduled for May 8.

On Feb. 26, the former Bayer chemicals arm, spun off in 2004, said that due to unexpected negative development in its rubber business, it had taken an impairment charge of €257 million for the fourth quarter of 2013 and expected to incur a loss for the full year.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read